Bio-Light Israeli Life Sciences Investments Ltd. (TASE:BOLT) portfolio company OBEcure Ltd. has obtained regulatory approval to conduct a follow-on trial to test combining its obesity treatment, Histalean, with Eli Lilly's (NYSE: LLY) anti-psychotic drug Zyprexa for the treatment of schizophrenia. The trial will be conducted in Romania.
Eli Lilly's Zyprexa is effective against schizophrenia, but causes obesity as a side effect.
The trial code is BET-216, and follows the successful BET-209 trial. The BET-216 trial will test the tolerability and effectiveness of the obesity drug in increasingly larger doses. The company has begun recruiting patients, and expects to complete the trial in October.
Bio-Light's share price fell 0.3% to NIS 0.447 in morning trading today.
Published by Globes [online], Israel business news - www.globes-online.com - on July 14, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010